Literature DB >> 33154536

Trends in oncology drug innovation in China.

Guanqiao Li, Yunhe Qin, Cuicui Xie, Yi-Long Wu, Xiaoyuan Chen.   

Abstract

Year:  2021        PMID： 33154536     DOI： 10.1038/d41573-020-00195-w

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  7 in total

Review 1.  Intraoperative fluorescence molecular imaging accelerates the coming of precision surgery in China.

Authors:  Zeyu Zhang; Kunshan He; Chongwei Chi; Zhenhua Hu; Jie Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-01       Impact factor: 10.057

2.  Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer.

Authors:  Xia Luo; Qiao Liu; Zhen Zhou; Lidan Yi; Liubao Peng; Xiaomin Wan; Xiaohui Zeng; Chongqing Tan; Sini Li
Journal:  Front Pharmacol       Date:  2022-04-19       Impact factor: 5.988

3.  The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.

Authors:  Xia Luo; Zhen Zhou; Xiaohui Zeng; Qiao Liu
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

4.  Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.

Authors:  Yichen Zhang; Huseyin Naci; Anita K Wagner; Ziyue Xu; Yu Yang; Jun Zhu; Jiafu Ji; Luwen Shi; Xiaodong Guan
Journal:  JAMA Netw Open       Date:  2022-08-01

5.  Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China.

Authors:  Dongchu Zhou; Xia Luo; Zhen Zhou; Xiaohui Zeng; Xiaomin Wan; Chongqing Tan; Qiao Liu
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

6.  Gene and cell therapies in China: booming landscape under dual-track regulation.

Authors:  Chen Yin; Jianchao Gao; Guanqiao Li; Hongxi Hu; Liyun Zhou; Shuang Lu; Xiaoyuan Chen
Journal:  J Hematol Oncol       Date:  2022-10-05       Impact factor: 23.168

7.  Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.

Authors:  Xia Luo; Zhen Zhou; Xiaohui Zeng; Liubao Peng; Qiao Liu
Journal:  Front Public Health       Date:  2022-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.